IMPORTANT SAFETY INFORMATION Prescribing Information

Indication: LEXIVA is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection. The PI-experienced patient study was not large enough to reach a definitive conclusion that LEXIVA/ritonavir and lopinavir/ritonavir are clinically equivalent. Once-daily administration of LEXIVA/ritonavir is not recommended for adult PI-experienced patients or any pediatric patients.

Important Safety Information: LEXIVA is contraindicated in patients with previously demonstrated clinically significant hypersensitivity to any of the components of this product or to amprenavir. LEXIVA is contraindicated with ergot derivatives, PROPULSID^®*(cisapride), ORAP^®* (pimozide), VERSED^®* (midazolam), HALCION^®*(triazolam), rifampin, MEVACOR^®* (lovastatin), ZOCOR^®* (simvastatin),RESCRIPTOR^®* (delavirdine), or St. John’s wort (Hypericum perforatum). If LEXIVA is coadministered with ritonavir, TAMBOCOR^®* (flecainide) and RYTHMOL^®* (propafenone) are also contraindicated. CONTINUED BELOW

ViiV for You

ViiV Healthcare wants to help your patients to get the drugs they need, even if they don't take our medicines. To learn more about how your patients can save on medicines and ViiV Healthcare's available drug savings programs, call us toll-free Monday through Friday at 1-866-GSK-FOR-U (1-866-475-3678) between 8:00 am and 8:00 pm Eastern Time, or contact us online.

Being a leader brings responsibility. We know that access to medicines is an important issue in this country, because many people don't have prescription drug coverage. In response, ViiV Healthcare has developed a number of patient support programs, including the GSK HIV Patient Savings Card, to help patients better adhere to the certain ViiV Healthcare HIV medicines.

Patient assistance programs

ViiV Healthcare's patient assistance programs provide prescription medicines to low-income, uninsured patients free or at very low cost. In addition, GlaxoSmithKline operates several programs, including:

Commitment to Access, which covers cancer treatments
Bridges to Access, which covers other medicines for outpatients
GSK Access, which provides free GlaxoSmithKline medicines to people enrolled in a Medicare drug plan who meet program requirements

GlaxoSmithKline was the first pharmaceutical company in the US to offer a card providing prescription drug help to low-income seniors and disabled people. In 2002, GlaxoSmithKline and 6 other pharmaceutical companies established the Together Rx card, which provides participating companies' discounts on over 100 prescription medicines for low-income senior citizens who are eligible for Medicare.

Today, we're committed to improving the quality of human life and contributing to a better future for all. That's why we're working to help people who need prescription drug help. Contact members of the ViiV Healthcare team who are available to help patients with their prescription drug coverage questions and concerns. To learn more about ViiV Healthcare, visit our company Web site.

Important Safety Information

Indication

LEXIVA is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection.

The PI-experienced patient study was not large enough to reach a definitive conclusion that LEXIVA/ritonavir and lopinavir/ritonavir are clinically equivalent.
Once-daily administration of LEXIVA/ritonavir is not recommended for adult PI-experienced patients or any pediatric patients.

Important Safety Information

LEXIVA is contraindicated in patients with previously demonstrated clinically significant hypersensitivity to any of the components of this product or to amprenavir
LEXIVA is contraindicated with ergot derivatives, PROPULSID^® (cisapride), ORAP^® (pimozide), VERSED^® (midazolam), HALCION^® (triazolam), rifampin, MEVACOR^® (lovastatin), ZOCOR^® (simvastatin), RESCRIPTOR^® (delavirdine), or St. John's wort (Hypericum perforatum). If LEXIVA is coadministered with ritonavir, TAMBOCOR^® (flecainide) and RYTHMOL^® (propafenone) are also contraindicated
Hyperglycemia, new onset or exacerbations of diabetes mellitus, and spontaneous bleeding in hemophiliacs have been reported with protease inhibitors
Treatment with LEXIVA/r has resulted in increases in the concentration of triglycerides and cholesterol. Triglyceride and cholesterol testing should be performed prior to initiating therapy with LEXIVA and at periodic intervals during therapy
Caution should be exercised when administering LEXIVA to patients with hepatic impairment, including those with hepatitis B or C or marked elevations in transaminases prior to treatment. Increased AST/ALT monitoring should be considered in these patients
LEXIVA taken with oral contraceptives may alter hormonal levels. LEXIVA plus ritonavir taken with oral contraceptives may result in clinically significant hepatic transaminase elevations. Therefore, alternate methods of non-hormonal contraception are recommended
Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including LEXIVA. During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection, cytomegalovirus, Pneumocystis jirovecii pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment
Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and "cushingoid appearance," have been observed in patients receiving antiretroviral therapy. The causal relationship, mechanism, and long-term consequences of these events are currently unknown
LEXIVA should be used with caution in patients with a known sulfonamide allergy
Cases of nephrolithiasis were reported during post-marketing surveillance in HIV-infected patients receiving fosamprenavir calcium. If signs or symptoms of nephrolithiasis occur, temporary interruption or discontinuation of therapy may be considered.
Severe or life-threatening skin reactions were reported in <1% of 700 patients treated with LEXIVA in clinical studies, including 1 case of Stevens-Johnson syndrome
Skin rash (all grades, without regard to causality) occurred in approximately 19% of patients treated with LEXIVA in the pivotal efficacy studies. This led to the discontinuation of LEXIVA in <1% of patients

Other Drug Interactions

Caution should be used when coadministering medications that are substrates, inhibitors, or inducers of CYP3A4, or potentially toxic medications that are metabolized by CYP3A4
Serious and/or life-threatening drug interactions could occur between LEXIVA and CORDARONE^® (amiodarone), lidocaine (systemic), tricyclic antidepressants, and quinidine. Concentration monitoring of these agents is recommended if these agents are used concomitantly with LEXIVA
Particular caution should be used when prescribing phosphodiesterase (PDE-5) inhibitors for erectile dysfunction (eg, sildenafil or vardenafil) in patients receiving LEXIVA
This list of potential drug interactions is not complete

Resistance

Because the potential for HIV cross-resistance among protease inhibitors has not been fully explored, it is unknown what effect therapy with LEXIVA will have on the activity of subsequently administered protease inhibitors
Clinical relevance of resistance data is unknown

Dosing | Data on LEXIVA | Healthcare providers’ tool kit | Resources | Risk & Side Effects